SuperworthArriVent BioPharma market cap AVBP
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $1B
- Highest close in our data
- $1.6B
- Jul 2026
ArriVent BioPharma is worth $1B at the close on Oct 23, 2026, at $21.00 a share.
That is up 37% over the last year.
Its highest close in our data was $1.6B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1B | $821.5M | $1.6B | +14% |
| 2025 | $907M | $558.5M | $1B | −1% |
| 2024 | $918.6M | $592.8M | $1.1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest ArriVent BioPharma's size, closest first, today.
| Company | Market cap |
|---|---|
| AVBPArriVent BioPharma | $1B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| ABUSArbutus Biopharma | $831M |
| COLLCollegium Pharmaceutical | $747.5M |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.5B |
| PAHCPhibro Animal Health | $1.6B |
| ANIPANI Pharmaceuticals | $1.7B |
| CRMDCorMedix | $611.9M |
| ZVRAZevra Therapeutics | $582.6M |
| Peer median | $1.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on ArriVent BioPharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.